Memarpour Sara, Khalili-Tanha Ghazaleh, Ghannad Awa Alizadeh, Razavi Masoud Sharifian, Joudi Mona, Joodi Marjan, Ferns Gordon A, Hassanian Seyed Mahdi, Khazaei Majid, Avan Amir
Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of biological sciences, California state University, Sacramento, California, United States.
Curr Cancer Drug Targets. 2021;21(8):676-688. doi: 10.2174/1568009621666210311090531.
Gastrointestinal (GI) cancer is one of the most common cancers globally. Genetic and epigenetic mechanisms are involved in its pathogenesis. The conventional methods for diagnosis and screening for GI cancers are often invasive and have other limitations. In the era of personalized medicine, a novel non-invasive approach called liquid biopsy has been introduced for the detection and management of GI cancers, which focuses on the analysis of Circulating Tumor Cells (CTCs) and circulating cell-free tumor DNA (ctDNA). Several studies have shown that this new approach allows for an improved understanding of GI tumor biology and will lead to an improvement in clinical management. The aim of the current review is to explore the clinical applications of CTCs and ctDNA in patients with GI cancer.
胃肠道（GI）癌是全球最常见的癌症之一。遗传和表观遗传机制参与其发病过程。传统的胃肠道癌诊断和筛查方法通常具有侵入性且存在其他局限性。在个性化医疗时代，一种名为液体活检的新型非侵入性方法已被引入用于胃肠道癌的检测和管理，该方法侧重于循环肿瘤细胞（CTC）和循环游离肿瘤DNA（ctDNA）的分析。多项研究表明，这种新方法有助于更好地理解胃肠道肿瘤生物学，并将改善临床管理。本综述的目的是探讨CTC和ctDNA在胃肠道癌患者中的临床应用。
